Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Olanow

Showing results (31-40 of 124) with videos related to

Pageof 13
Sort By:
Annual Review of Neuroscience|April 15, 1999
Etiology and pathogenesis of Parkinson's diseaseC W Olanow, W G Tatton
Current Opinion in Neurology|December 1, 1994
Metals and free radicals in neurodegenerationC W Olanow, G W Arendash
Annals of Neurology|September 28, 1998
Dopamine agonists and neuroprotection in Parkinson's diseaseC W Olanow, P Jenner, D Brooks
Experimental Neurology|June 18, 2017
Clinical approaches to the development of a neuroprotective therapy for PDC W Olanow, K Kieburtz, R Katz
Trends in Neurosciences|October 29, 2000
Continuous dopamine-receptor stimulation in early Parkinson's diseaseW Olanow, A H Schapira, O Rascol
Neurology|March 1, 1981
The effects of salicylate on the pharmacokinetics of phenytoinC W Olanow, A L Finn, C Prussak
Journal of Neurochemistry|January 1, 1997
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitroC Mytilineou, P M Radcliffe, C W Olanow
Annals of Neurology|September 28, 1998
Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration?D P Perl, C W Olanow, D Calne
Annals of Neurology|September 28, 1998
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotectionM C Rodriguez, J A Obeso, C W Olanow
Clinical Neuropharmacology|December 1, 1989
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover studyC W Olanow, E G Werner, L L Gauger
Pageof 13

Showing results (31-40 of 124) with videos related to

Sort By:
Pageof 13
Annual Review of Neuroscience|April 15, 1999
Etiology and pathogenesis of Parkinson's diseaseC W Olanow, W G Tatton
Current Opinion in Neurology|December 1, 1994
Metals and free radicals in neurodegenerationC W Olanow, G W Arendash
Annals of Neurology|September 28, 1998
Dopamine agonists and neuroprotection in Parkinson's diseaseC W Olanow, P Jenner, D Brooks
Experimental Neurology|June 18, 2017
Clinical approaches to the development of a neuroprotective therapy for PDC W Olanow, K Kieburtz, R Katz
Trends in Neurosciences|October 29, 2000
Continuous dopamine-receptor stimulation in early Parkinson's diseaseW Olanow, A H Schapira, O Rascol
Neurology|March 1, 1981
The effects of salicylate on the pharmacokinetics of phenytoinC W Olanow, A L Finn, C Prussak
Journal of Neurochemistry|January 1, 1997
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitroC Mytilineou, P M Radcliffe, C W Olanow
Annals of Neurology|September 28, 1998
Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration?D P Perl, C W Olanow, D Calne
Annals of Neurology|September 28, 1998
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotectionM C Rodriguez, J A Obeso, C W Olanow
Clinical Neuropharmacology|December 1, 1989
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover studyC W Olanow, E G Werner, L L Gauger
Pageof 13